Ceres Nanosciences, Inc.
PrivateLast Round
Grant
Sep 29, 2025
Total Funding Raised
$34.03M
Company Overview
Ceres Nanosciences, Inc. operates in Healthcare & Life Sciences and is based in Manassas, Virginia. Its latest recorded funding round was a Grant round in September 2025.
Ceres Nanosciences, Inc. is a life sciences company that develops and commercializes innovative sample preparation products based on its proprietary Nanotrap® particle technology to improve diagnostic testing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ceres Nanosciences, Inc. Comparables
Compare Ceres Nanosciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MagBioscience | 76% | |
| Thermo Fisher Scientific Inc. | 72% | |
| Streck | 67% |
For institutional investors. Book with your work email.
Ceres Nanosciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 29, 2025 | ||||
| Grant | Aug 13, 2025 | ||||
| Grant | Dec 1, 2022 | ||||
| Series B | Sep 14, 2022 | ||||
| Grant | Apr 21, 2021 | ||||
Grant | Sep 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ceres Nanosciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pactolus Ventures | Series A, Series A Extension |
| University of Virginia LVG Seed Fund | Series A, Series A Extension |
| U.S. Department of Defense | Grant |
| NIH RADx | Grant |
| Gates Family Foundation | Grant |
| Bill & Melinda Gates Foundation | Grant |
| U.S. Department of War | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
Added MS Wil, a healthcare/medical diagnostics company, as a customer.
- Sep 29, 2025
$500K round led by Gates Family Foundation.
For institutional investors. Book with your work email.
Ceres Nanosciences, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ceres Nanosciences, Inc.'s valuation, stock price, and market status.
Is Ceres Nanosciences, Inc. a public or private company?
Ceres Nanosciences, Inc. is a private company.
What is the current stock price of Ceres Nanosciences, Inc.?
Ceres Nanosciences, Inc. is a private company, so its shares have no public market price. Caplight tracks Ceres Nanosciences, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ceres Nanosciences, Inc. worth (valuation)?
Valuation information for Ceres Nanosciences, Inc. is not publicly available.
Can I buy Ceres Nanosciences, Inc. stock?
Ceres Nanosciences, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ceres Nanosciences, Inc.'s last funding round?
Ceres Nanosciences, Inc.'s most recent funding round was Grant on September 29, 2025.
Who are the main investors in Ceres Nanosciences, Inc.?
Key investors in Ceres Nanosciences, Inc. include Gates Family Foundation, GreyBird Ventures.
Will Ceres Nanosciences, Inc. IPO soon?
No public IPO plans have been announced for Ceres Nanosciences, Inc..
How can I track Ceres Nanosciences, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ceres Nanosciences, Inc.'s shares on secondary markets.